Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk
Atheroscler Suppl. 2020 Dec;42:e1-e5. doi: 10.1016/j.atherosclerosissup.2021.01.001.ABSTRACTThe 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the Management of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk, that were recently released by the United States and Europe, provide new recommendations for the management of blood lipid levels based on the latest evidence. Despite many common points, there are several diff...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Lale Tokg özoğlu Manuela Casula Angela Pirillo Alberico L Catapano Source Type: research
The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study
CONCLUSIONS: The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population.PMID:33589219 | DOI:10.1016/j.atherosclerosissup.2021.01.004 (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Jacek J J óźwiak Krzysztof Studzi ński Tomasz Tomasik Adam Windak Miros ław Mastej Alberico L Catapano Kausik K Ray Dimitri P Mikhailidis Peter P Toth George Howard Gregory Y H Lip Maciej Tomaszewski Fadi J Charchar Naveed Sattar Bryan Williams Thomas Source Type: research
Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy
Atheroscler Suppl. 2020 Dec;42:e25-e29. doi: 10.1016/j.atherosclerosissup.2021.01.005.ABSTRACTThe availability of efficient lipid-lowering drugs has substantially reduced the incidence and mortality for cardiovascular disease (CVD). Despite that, CVD still represents a major cause of death and disability; efforts are thus required to prevent this disease, since reducing the established CV risk factors may slow or prevent the onset of cardiovascular events. Current guidelines recommend a healthier lifestyle for all CV risk categories, as it may have a beneficial impact on several risk factors; in individuals with a low-to-m...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Bernhard F öger Catriona Jennings Angela Pirillo Lale Tokg özoğlu Matteo Pirro Alberico L Catapano Source Type: research
Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients
Atheroscler Suppl. 2020 Dec;42:e30-e34. doi: 10.1016/j.atherosclerosissup.2021.01.006.ABSTRACTThe widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have rev...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Gerald F Watts Alberico L Catapano Luis Masana Alberto Zambon Angela Pirillo Lale Tokg özoğlu Source Type: research
How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia
Atheroscler Suppl. 2020 Dec;42:e35-e40. doi: 10.1016/j.atherosclerosissup.2021.01.007.ABSTRACTFamilial hypercholesterolemia (FH) is a common genetic disorder of lipid metabolism, still underdiagnosed and undertreated in the general population. Pathology registers could play a crucial role in the creation of a comprehensive and integrated global approach to cover all aspects of this disease. Systematic data collection of patients affected by FH has increased dramatically worldwide in the past few years. Moreover, results from registers already established for the longest time showed their potentialities in the implementatio...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Marta Gazzotti Manuela Casula Elena Olmastroni Maurizio Averna Marcello Arca Alberico L Catapano Source Type: research
Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies
CONCLUSIONS: Developing effective public health strategies for the prevention, detection and treatment of MetS should be an urgent priority to reduce the burden of CVD, not only in subjects at high/very high CV risk, but also in those characterized by a lower risk, as even rare CV events that come from low risk group bring a tangible burden to healthcare systems.PMID:33589223 | DOI:10.1016/j.atherosclerosissup.2021.01.008 (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Asiiat S Alieva Elena Olmastroni Olga V Reutova Oxana P Rotar Alexandra O Konradi Evgeny V Shlyakhto Andrea Baragetti Liliana Grigore Fabio Pellegatta Manuela Casula Elena Tragni Alberico L Catapano Source Type: research
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project
CONCLUSIONS: Contemporary lipid management of very high CV risk patients is sub-optimal despite available treatments. Greater efforts are warranted to optimize cardiovascular prevention.PMID:33589224 | DOI:10.1016/j.atherosclerosissup.2021.01.009 (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Ulf Landmesser Angela Pirillo Michel Farnier J Wouter Jukema Ulrich Laufs Fran çois Mach Luis Masana Terje R Pedersen Fran çois Schiele Gabriel Steg Marco Tubaro Azfar Zaman Pepe Zamorano Alberico L Catapano Source Type: research
Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives
Atheroscler Suppl. 2020 Dec;42:e59-e64. doi: 10.1016/j.atherosclerosissup.2021.01.010.ABSTRACTPost-acute coronary syndrome (ACS) patients are at very high cardiovascular risk. Despite current guidelines strongly recommend to reduce LDL-C levels and initiation of high-intensity statins as early as possible in patients admitted with an ACS, less than half of ACS patients receive a high intensity statin, and a high percentage of has LDL-C well above the goal despite therapy. There are multiple reasons for that, including physician lack of guideline adherence, patient lack of compliance with treatment, and lack of standardized...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Marco Alings Olivier Descamps Benoit Guillon Margret Leosdottir Aldo P Maggioni Lluis Recasens Walter S Speidl Rosario V Tripodi Ulf Landmesser Alberico L Catapano Angela Pirillo Source Type: research
Lipid Clinics Network. Rationale and design of the EAS global project
Atheroscler Suppl. 2020 Dec;42:e6-e8. doi: 10.1016/j.atherosclerosissup.2021.01.002.ABSTRACTThe evidence of the causal role of low-density lipoprotein cholesterol in the development of atherosclerotic cardiovascular disease is well-established. The clearly identified common position of the European guidelines proclaims necessity to decrease LDL-C concentrations based on a proper risk stratification. However, current worldwide situation with the lipid management still demonstrates inadequate dyslipidemia control, that is probably related to a healthcare system issues. As the need to standardize and implement approaches foll...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Asiiat S Alieva Lale Tokg özoğlu Kausik K Ray Alberico L Catapano Source Type: research
Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool
Atheroscler Suppl. 2020 Dec;42:e65-e71. doi: 10.1016/j.atherosclerosissup.2021.01.011.ABSTRACTPost-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. In 2018, the ACS EuroPath Survey, performed in collaboration with 555 European cardiologists, identified a sub-optimal LDL-C management in post-ACS patients. Based on these premises, the ACS EuroPath II project led to the development of a self-assessment tool to improve lipid management in these very high risk patients, taking into consideration the new 2019 ESC/EAS...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Alessandro Sionis Alberico L Catapano Gaetano M De Ferrari Dariusz Dudek J Wouter Jukema Ulf Landmesser Angela Pirillo Fran çois Schiele Azfar Zaman Jose L Zamorano Source Type: research
'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members
Atheroscler Suppl. 2020 Dec;42:e9-e14. doi: 10.1016/j.atherosclerosissup.2021.01.003.ABSTRACTTo better understand the level of knowledge and interest in 'diet and lifestyle' for cholesterol management and CVD prevention, European Atherosclerosis Society (EAS) members were invited to take part in an online survey. In total, 269 EAS members participated of which 64 (24%) were students/postdocs, 102 (38%) researchers involved with CVD-related research and 103 (38%) doctors and clinicians who directly interact with patients. All (99%) of the participants either agreed or strongly agreed that 'diet and lifestyle' have a role to...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Elke A Trautwein Alberico L Catapano Lale Tokg özoğlu Source Type: research
Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk
Atheroscler Suppl. 2020 Dec;42:e1-e5. doi: 10.1016/j.atherosclerosissup.2021.01.001.ABSTRACTThe 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the Management of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk, that were recently released by the United States and Europe, provide new recommendations for the management of blood lipid levels based on the latest evidence. Despite many common points, there are several diff...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Lale Tokg özoğlu Manuela Casula Angela Pirillo Alberico L Catapano Source Type: research
The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study
CONCLUSIONS: The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population.PMID:33589219 | DOI:10.1016/j.atherosclerosissup.2021.01.004 (Source: Atherosclerosis Supplements)
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Jacek J J óźwiak Krzysztof Studzi ński Tomasz Tomasik Adam Windak Miros ław Mastej Alberico L Catapano Kausik K Ray Dimitri P Mikhailidis Peter P Toth George Howard Gregory Y H Lip Maciej Tomaszewski Fadi J Charchar Naveed Sattar Bryan Williams Thomas Source Type: research
Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy
Atheroscler Suppl. 2020 Dec;42:e25-e29. doi: 10.1016/j.atherosclerosissup.2021.01.005.ABSTRACTThe availability of efficient lipid-lowering drugs has substantially reduced the incidence and mortality for cardiovascular disease (CVD). Despite that, CVD still represents a major cause of death and disability; efforts are thus required to prevent this disease, since reducing the established CV risk factors may slow or prevent the onset of cardiovascular events. Current guidelines recommend a healthier lifestyle for all CV risk categories, as it may have a beneficial impact on several risk factors; in individuals with a low-to-m...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Bernhard F öger Catriona Jennings Angela Pirillo Lale Tokg özoğlu Matteo Pirro Alberico L Catapano Source Type: research
Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients
Atheroscler Suppl. 2020 Dec;42:e30-e34. doi: 10.1016/j.atherosclerosissup.2021.01.006.ABSTRACTThe widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have rev...
Source: Atherosclerosis Supplements - February 16, 2021 Category: Cardiology Authors: Gerald F Watts Alberico L Catapano Luis Masana Alberto Zambon Angela Pirillo Lale Tokg özoğlu Source Type: research
